Catherine G. Callahan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Catherine G. Callahan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Harold
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
41 shared publications - Brian Tran
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
41 shared publications - Brynne Raines
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
41 shared publications - Caitlin M. O'Connor
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
41 shared publications - Charles A. Nino
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
41 shared publications - Derek J. Taylor
Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA
41 shared publications
Latest Publications
- 14 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (871)
Restoration of PP2A AαB56αC trimer formation by RPT04402 molecular glue in high-grade uterine cancer
The incidence and mortality of high-grade endometrial cancers are increasing, and heterozygous hotspot mutations in PPP2R1A are drivers of the most aggressive forms of uterine cancer. PPP2R1A encodes the Aα scaffolding subunit of the heterotrimeric phosphatase PP2A. These recurrent mutations, specifically at the Pro 179 and Ser 256 residues, disrupt the binding of tumor-suppressive substrate-directing B56 and B55 subunits to the PP2A scaffolding subunit while maintaining binding to other regulatory subunits. Here, we identified a series of molecular glues that correct PP2A trimer formation in the context of the P179R (Pro 179 →Arg) and S256F (Ser 256 →Phe) mutants. A small-molecule library was designed to fit into the pocket at the binding interface of the Aα/B56α/C heterotrimer. The lead molecule, RPT04402, promoted B56α heterotrimerization to the Aα P179R and Aα S256F mutant scaffolds. In mice, RPT04402 treatment drove tumor regressions and extended median survival in multiple independent mutant cell lines and patient-derived xenografts, proving a robust single-agent activity. This activity was abrogated upon knockout of B56α. Combined, these data demonstrate that PP2A molecular glues are a promising first-in-class therapy that might benefit patients with PPP2R1A mutant uterine cancer by targeting a driver of this aggressive disease.
- 14 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (871)
Restoration of PP2A AαB56αC trimer formation by RPT04402 molecular glue in high-grade uterine cancer
The incidence and mortality of high-grade endometrial cancers are increasing, and heterozygous hotspot mutations in PPP2R1A are drivers of the most aggressive forms of uterine cancer. PPP2R1A encodes the Aα scaffolding subunit of the heterotrimeric phosphatase PP2A. These recurrent mutations, specifically at the Pro 179 and Ser 256 residues, disrupt the binding of tumor-suppressive substrate-directing B56 and B55 subunits to the PP2A scaffolding subunit while maintaining binding to other regulatory subunits. Here, we identified a series of molecular glues that correct PP2A trimer formation in the context of the P179R (Pro 179 →Arg) and S256F (Ser 256 →Phe) mutants. A small-molecule library was designed to fit into the pocket at the binding interface of the Aα/B56α/C heterotrimer. The lead molecule, RPT04402, promoted B56α heterotrimerization to the Aα P179R and Aα S256F mutant scaffolds. In mice, RPT04402 treatment drove tumor regressions and extended median survival in multiple independent mutant cell lines and patient-derived xenografts, proving a robust single-agent activity. This activity was abrogated upon knockout of B56α. Combined, these data demonstrate that PP2A molecular glues are a promising first-in-class therapy that might benefit patients with PPP2R1A mutant uterine cancer by targeting a driver of this aggressive disease.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Key Resources Table from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Table of key resources and reagents used in this manuscript.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKey Resources Table from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Table of key resources and reagents used in this manuscript.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
B56-alpha OE Vector Map from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Vector map for the B56-alpha overexpression (OE) plasmid
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessB56-alpha OE Vector Map from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Vector map for the B56-alpha overexpression (OE) plasmid
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Raw PCA Data from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Raw data of the PCA analysis from the Broad Institute Cell Line Encyclopedia
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessRaw PCA Data from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Raw data of the PCA analysis from the Broad Institute Cell Line Encyclopedia